The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter

Overview

The investigators investigated the ability of narrowband ultraviolet B (nbUVB) treatment in the maintenance of vitamin D levels achieved during the summer in Finland. The investigators randomized 37 subjects into groups of 17 and 18 subjects. The other group received 2 standard erythema doses (SED) nbUVB exposure every other week until week 24, and serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30. The control group was not illuminated and serum samples were analyzed correspondingly. Punch biopsies were taken at the onset and at week 14 for CYP27A1 and CYP27B1 enzyme expression level analyses.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2014

Detailed Description

The investigators investigated the ability of narrowband ultraviolet B (nbUVB) treatment in the maintenance of vitamin D levels achieved during the summer in Finland. The investigators randomized 37 subjects into groups of 17 and 18 subjects. The other group received 2 standard erythema doses (SED) nbUVB exposure every other week until week 24, and serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30. The control group was not illuminated and serum samples were analyzed correspondingly. 6mm punch biopsies were taken at the onset and at week 14 for CYP27A1 and CYP27B1 enzyme expression level analyses.

Interventions

  • Radiation: nbUVB
    • 2 SED nbUVB exposure will be given every other week

Arms, Groups and Cohorts

  • Experimental: nbUVB
    • 2 SED dose of nbUVB will be given every other week for this intervention group.
  • No Intervention: control
    • No nbUVB illumination will be given for the control group.

Clinical Trial Outcome Measures

Primary Measures

  • 25(OH)D level
    • Time Frame: up to 30 weeks
    • Serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30.

Secondary Measures

  • CYP27A1 and CYP27B1 enzyme expression levels
    • Time Frame: up to 14 weeks
    • CYP27A1 and CYP27B1 enzyme expression levels will be analysed from 6mm punch biopsies at the onset and at week 14.

Participating in This Clinical Trial

Inclusion Criteria

  • age over 18 – Fitzpacker's skin type II-IV Exclusion Criteria:

  • age under 18 – diseases that inhibit vitamin D metabolism or absorption – Fitzpacker's skin type I – history of skin cancer – vitamin D substitution 1 month before baseline or during study – sun holidays 1 month before baseline or during study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Joint Authority for Päijät-Häme Social and Health Care
  • Collaborator
    • Tampere University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Toni T Karppinen, MD, Principal Investigator, Päijät Häme Central Hospital
    • Erna Snellman, professor, Study Director, Tampere University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.